bought a new stake in shares of Cellectis during the third quarter valued at approximately $197,000. Millennium Management LLC now owns 679,966 shares of the biotechnology company’s stock valued at $1,428,000 after acquiring an additional 106,125 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Cellectis by 18.5% during the fourth quarter. now owns 1,348,312 shares of the biotechnology company’s stock valued at $3,816,000 after acquiring an additional 133,587 shares in the last quarter. increased its holdings in shares of Cellectis by 11.0% during the second quarter. State Street Corp now owns 253,725 shares of the biotechnology company’s stock worth $718,000 after purchasing an additional 134,164 shares in the last quarter. State Street Corp increased its holdings in Cellectis by 112.2% in the second quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock worth $2,789,000 after purchasing an additional 376,862 shares in the last quarter. Jane Street Group LLC increased its holdings in Cellectis by 166.5% in the first quarter.
Institutional Trading of CellectisĪ number of hedge funds have recently made changes to their positions in CLLS. Based on an average trading volume of 153,400 shares, the days-to-cover ratio is currently 2.6 days. As of February 15th, there was short interest totalling 393,800 shares, an increase of 5.4% from the January 31st total of 373,600 shares. ( NASDAQ:CLLS – Get Rating) was the recipient of a large increase in short interest during the month of February.
0 kommentar(er)
